August 2018

New Product - Maviret

Glecaprevir/pibrentasvir (Maviret) contains two pangenotypic direct acting antivirals, glecaprevir (NS3/4A protease inhibitor) and pibrentasvir (NS5A inhibitor), targeting multiple steps in the hepatitis C virus (HCV) lifecycle. Maviret is indicated for the treatment of adults with chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection, with or without compensated cirrhosis. This includes patients with HCV genotype 1 infection who were previously treated with either a regimen of an NS5A inhibitor or with an NS3/4A protease inhibitor but not both classes of inhibitors. Maviret is contraindicated with the following: severe hepatic impairment (Child-Pugh C); atazanavir containing products, atorvastatin, simvastatin, dabigatran etexilate, ethinylestradiol containing products, rifampicin. Maviret fixed dose combination tablets containing glecaprevir 100 mg and pibrentasvir 40 mg are available in packs of 84.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia┬áPty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629